IL17RA and myeloid sarcoma: BCL11B, ETS1, GATA3, IL17R, NFIL3, and ID3 were upregulated in ILCs of MS patients, whereas TOX, RUNX3, ID2, and AHR were downregulated (Fig. 3B) potentially indicating loss of regulatory mechanisms.